

## DAFTAR PUSTAKA

1. American diabetes association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2006;29 suppl 1:S43-8.
2. World Health Organization. Definition and diagnosis of Diabetes Mellitus and intermediate hyperglycemia. Geneva, Switzerland, IDF;2006:5.
3. Wild S, Roglic C, Green A, Sicree R, King H. Global prevalence of diabetes : estimates for the year 2000 and projection for 2030. *Diabetes Care* 2004; 27(5):1047-53.
4. PB. PERKENI. Konsensus pengelolaan Diabetes Melitus di Indonesia 2006. PB Perkeni. Jakarta. 2006
5. Shihonara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K et al. A new spontaneously diabetic non-obese Torri rat strain with severe ocular complications. *Int J Experimental Diab. Res* 1999;1:89-100.
6. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of rat pancreas. *Physiol. Res.* 2001;50:536-46.
7. Abeeleh MA, Ismail ZB, Alzaben KR, Abu-halaweh SA, Al-elsa MK, Abuabeeleh J et al. Induction of diabetes mellitus in rats using intraperitoneal streptozotocin : a compatison between 2 strains of rats. *Euro J Sci Res* 2009;32(3):398-402.
8. Ramesh B, Pugalendi KV. Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats. *J Med Food* 2006 ;9(4) 562–6.
9. Ndrepepa G, Kastrati A, Braun A, Koch W, Kolling K, Mehilli J, Schomig A. Circulating homocysteine levels in patients with type 2 diabetes mellitus. *Nutr, Metab & Cardiovas Dis* 2008;18:66-73.
10. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. *Diabet care* 2001;24:533-8.
11. Mazza A, Bossone E, Mazza F, Distanto A. Reduced serum homocysteine levels in type 2 diabetes. *Nutr Metab Cardiovasc Dis* 2005;15:118-24.
12. Mahboob M, Rahman MF, Grover P. Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. *Singapore Med J* 2005;46(7):322-4.
13. Gonzales-C, Deulofeu R, Mitjavila J, Galdon G, Ortega E, Caixas A et al. Plasma homocysteine is not increase in microalbuminuric patients with type 2 diabetes without clinical cardiovascular disease. *Diabet care* 2002;25(3): 632-4.
14. Kalaivanam KN, Dharmalingram M, Marcus SR. Lipid peroxidation in type 2 diabetes mellitus. *Int J Diab Dev Ctries* 2006;26:30-2.
15. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease. *J Am Coll Cardiol* 2006;48:914 –23.

16. Dwivedi J, Sarkar PD. Lipoprotein A, homocysteine, lipid profile with oxidative stress in nephritic syndrome and cardiovascular nephropathy. *Int J Pharma and bio* 2010;4(1):B340-50.
17. Vermeulen EGJ, Stehouwer CDA, Valk J, Van der Knaap M, Van der berg M, Twisk JWR et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo controlled, randomized trial. *Europ J Clin Invest* 2004;34:256-61.
18. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus and atheroscleropathy: the pleiotropic effects of folat supplementation. *Nutr J* 2004;3:1-23.
19. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements :meta-analysis of randomized trials. *Br Med J* 1998;316:894-8.
20. Racek J, Rusnakova H, Trefil L, Siala KK. The influence of folat on homocysteine level and oxidative stress in patient with hyperlipidemia and hyperhomocysteinemia. *Physiol Res* 2005;54:87-95.
21. Díes N, Pérez R, Hurtado V, Santridián S. Hyperhomocysteinemia induced by dietary folate restriction cause kidney oxidative stress in rat. *Br J Nutr* 2005;94:204–210.
22. Nieman KM, Hartz CS, Szegedi SS, Garrow TA, Sparks JD, Schalinske KL. Folate status modulates the induction of hepatic glycine N-methyltransferase and homocysteine metabolism in diabetic rat. *Am J Physiol Endocrin Metab* 2006;291:E1235–E42.
23. Huang RF, Hsu YC, Lin HL, Yang FL. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. *J Nutr* 2001;131: 33–38.
24. Symon JD, Mullick AE, Ensunsa JL, Amy AM, Rutledge JC. Hyperhomocysteinemia Evoked by Folate Depletion: Effects on Coronary and Carotid Arterial Function. *Atheroscler Thromb Vasc Bio J* 2002;22:772-80.
25. Moat SJ, Hill MH, McDoweel IFW et al. Reduction in plasma total homocysteine through increasing folate intake in healthy individuals is not associated with changes in measures of antioxidant activity or oxidant damage. *Euro J Clin Nutr* 2003;57:483-89.
26. Lavin CH, Hudson PR, Mukherjee S, Davies GK, Williams CP, Harvey JN et al. Folate supplementation reduce serum Hsp70 levels in patient with type 2 diabetes. *Cell stress & chaperones* 2004;9(4):344-9.
27. Chang CM, Yu CC, Hsin-TeLu, Yi-Fang C, Huang RF. Folate deprivation promote mitochondrial oxidative decay:DNA large deletions, cytochrome c oxidase dysfunction, membrane depolarization and superoxide overproduction in rat liver. *Br J Nutri* 2007;97:855–63.
28. Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A. Effect of folat supplementation on serum homocysteine and plasma total antioxidant capacity

- in hipercolesterolemik adult under lovastatin treatment :a double blind randomized controlled trial. *Archive M Res* 2009; 40(5):380-6.
29. Etuk EU. Animals models for studying diabetes mellitus. *Agric. Biol. J. N. Am* 2010;1(2):130-4.
  30. Lenzen S. The mechanism of alloxan and streptozotocin induced diabetes. *Diabetologia* 2008;51:216–26.
  31. Escrig A, Marin R, Abreu B, Gonzales-mora JL, Mas M. change in mating behavior, erectile function and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rat. *Biol of repro* 2002;66:185-9.
  32. Arora S, Ojha SK, Vohora D. Characterization of streptozotocin induced diabetes mellitus in swiss albino mice. *Global J Pharmacol* 2009;3(2):81-4.
  33. Gouaille CB. Focus on homocysteine: What is homocysteine. 2001. Springer verlag france.
  34. Wijekoon E.P, Brosnan M.E and Brosnan J.T. Homocysteine metabolism in diabetes. *Biochem Soc Transact* 2007 ;35(5):1175-9.
  35. Lenz SR, Haynes WG. Homocysteine :is it a clinically important cardiovascular risk factor? *Cleve Clin J Med* 2004 ;71(9):729-34.
  36. Martin PJF, Galdien LC, Sauza FG, Andersen ML, Benevito-Silva A, Tufik S et el. Physiological variation in plasma total homocystein concentration in rats. *Life sciences* 2005;76:2621-9.
  37. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effect of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in rat. *Diabetes* 1998;47:1967-70.
  38. Winarsi H. Radikal bebas dan anti oksidan dalam Antioksidan alami dan radikal bebas: potensi dan aplikasinya dalam kesehatan. Yogyakarta. 2007:11-5.
  39. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement and significance. *Am J Clin Nutr* 1993;57:715S-25S.
  40. Karatas F, Karatepe M, Baysar A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography. *Anal Biochem* 2002;311:76-9.
  41. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derivad malondialdehyde in diabetes mellitus. *Diabetologi* 2000;43:550-7.
  42. Moussa SA. Oxidative stress in diabetes mellitus. *Romanian J Biophys* 2008;18(3):P225-36.
  43. Tandon V, Grupta BM, Tandon R. Free radicals/reactive oxygen species. *JK-Practitioner* 2005;12(3):143-8
  44. Johansen JS, Harris AK, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. *Cardiovasc Diabetology* 2005;4(5):1-11.
  45. Shenkin A, Baines M, Fell SG, Lyon TDG. Vitamin and trace elements. In *Tietz textbook clinical chemistry and molecular diagnostic 4<sup>ed</sup>*. Philadelphia : Elsevier Inc : 2006: 1075-1118.

46. Dimitrov DM, Rumrill PD Jr. Pretest posttest design and measurement of change. USA. IOS press 2003:159-65.
47. Charles River laboratories. Clinical laboratory parameters for CrI:CD(SD) rats. Charles River laboratories, March 2006:11.
48. World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine. Geneva, WHO; 2000 :28.
49. Rat homocysteine (Hcy) ELISA kit. (cited 03/03/2011). Available from:[http://search.cosmobio.co.jp/cosmo\\_search\\_p/search\\_gate2/docs/CSB\\_/CSBE08896R.20090603.pdf](http://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/CSB_/CSBE08896R.20090603.pdf).
50. Cayman chemical TBARS Assay Kit catalog no 10009055. (cited 20/07/2010) Available from : [http://www.bioassaysys.com/file\\_dir/DTBA.pdf](http://www.bioassaysys.com/file_dir/DTBA.pdf).
51. Dahlan S. Statistik deskriptif. Dalam Statistik untuk kedokteran dan kesehatan. Jakarta:ARKANS 2004:31-59.
52. Dahlan S. Uji hipotesis komparatif variabel numerik 2 kelompok. Dalam Statistik untuk kedokteran dan kesehatan. Jakarta:ARKANS, 2004:66-82.
53. Sastroasmoro S, Alan RT, Pandu R, Muljono W, Partini P, Kemas F. Pemilihan uji hipotesis. Dalam dasar-dasar metodologi penelitian klinis. Ed 2. Jakarta:Sagung Seto, 2002:240-57.
54. Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patient with type 2 diabetes mellitus. Tohoku J Exp Med 2004;203: 211-8.
55. Maharjan BR, Jha JC, Adhikari D, Vishwanath P, Baxi J, Alurkar VM et al. A study of oxidative stress, antioxidant status and lipid profile in diabetic patient in the western region of Nepal. Kathmandu Univ Med J 2008; 6(1): 16-22.
56. Bejma J, Ji LL. Aging and acut exercise enhance free radical generation in rat skeletal muscle. J Appl Physiol 1999; 87:465-70.
57. Caruso R, Campolo J, Sedda V, De Chiara B, Dellanoce C, Baudo F et all. Effect of homocysteine lowering by 5-methyltetrahydrofolate on redox status in hiperhomocysteinemia. J Cardiovasc Pharmacol<sup>TM</sup> 2006;47:549–55.